Human Resources

Human Insulin Drug Market Is Estimated To Witness High Growth Owing To Opportunity To Treat Diabetes

Poonam

Human Insulin Drug Market Is Estimated To Witness High Growth Owing To Opportunity To Treat Diabetes

Human insulin is a pharmaceutical product extracted from human or animal tissues and produced using recombinant DNA technology. It is widely used for diabetes treatment owing to its effectiveness in managing blood glucose levels. Insulin is essential for metabolism, and lack of its production results in diabetes. The increasing prevalence of type 1 and type 2 diabetes has boosted the demand for human insulin drugs globally. As per estimates, about 556 million people worldwide were diagnosed with diabetes in 2021, and this number is expected to rise to 700 million by 2045.

The global Human Insulin Drug Market is estimated to be valued at US$ 49411.32 Mn in 2023 and is expected to exhibit a CAGR of 6.1% over the forecast period 2023 to 2030, as highlighted in a new report published by Coherent Market Insights.

Market Opportunity:

The rising diabetic population globally presents lucrative opportunities for players in the human insulin drug market. According to the International Diabetes Federation, three in four people living with diabetes reside in low-and middle-income countries. However, access to healthcare remains a challenge in these regions. Manufacturers can expand their businesses in Asian and African countries by increasing access to cost-effective insulin drugs. Moreover, investments in new production technologies, such as development of ultra-rapid human insulin analogs along with devices like insulin pens and pumps for hassle-free administration, are expected to further propel the market growth during the forecast period. Establishing partnerships with hospitals and distributors in developing countries can help cater to the vast diabetic population still deprived of insulin treatment and management. This presents a remunerative market opportunity for pharmaceutical companies.

Porter's Analysis

Threat of new entrants: The human insulin drug market has high barrier for new entrants due to high R&D cost and regulatory hurdles. Manufacturing human insulin also requires specialized knowledge and infrastructure.

Bargaining power of buyers: Buyers have moderate bargaining power due to availability of substitutes and presence of many established manufacturers and suppliers. However, insulin is an essential drug so buyers cannot avoid purchasing.

Bargaining power of suppliers: A few biotechnology companies globally supply active pharmaceutical ingredients for human insulin production. This gives them considerable power over manufacturers.

Threat of new substitutes: Alternatives like GLP-1 receptor agonists and DPP-4 inhibitors pose threats but none can fully substitute insulin due to its unique function and use in advanced stages of diabetes.

Competitive rivalry: The market sees intense rivalry among major players to gain higher market share through new product launches, strengthening distribution networks and conducting awareness programs.

SWOT Analysis

Strength: Established production facilities and R&D capabilities. Insulin is an essential drug with inelastic demand.

Weakness: High dependency on few active pharmaceutical ingredient suppliers globally increases supply chain risks. Biosimilars erosion eats into market share of originator products.

Opportunity: Expanding patient pool of diabetes worldwide along with rising health awareness and income levels in developing regions.

Threats: Pricing pressures due to patent expiries. Stringent regulatory norms for quality and safety compliance during manufacturing.

Key Takeaways

The global Human Insulin Drug Market Growth is expected to witness high growth during the forecast period owing to the rising incidence of diabetes globally. The International Diabetes Federation estimates that approximately 537 million adults were living with diabetes in 2021 worldwide and the number is predicted to rise to 643 million by 2030 and 783 million by 2045.

Regional analysis: North America currently dominates the global market and is expected to retain its leading position during the forecast period due to high healthcare spending and technological advancements in the region. However, Asia Pacific is predicted to experience the highest growth rate owing to expanding diabetic population, growing health awareness, and increasing healthcare investments in countries like China and India.

Key players: Key players operating in the human insulin drug market are Ecolab Inc., Rollins Inc., Rentokil Initial Plc., ServiceMaster Company, LLC, Massey Services Inc., Arrow Exterminators Inc., Sanix Incorporated, Asante Inc., Dodson Pest Control, Inc., Target Specialty Products, Pelsis Ltd., Killgerm Ltd., WinField Solutions, LLC, and Univer Inc. Eli Lilly, Novo Nordisk and Sanofi are the major players for human insulin drug production globally. They focus on strengthening product portfolios through continuous R&D and capacity expansion.

For more insights, read- https://www.newsanalyticspro.com/human-insulin-drug-market-trends-size-and-share-analysis/

Poonam

Human Insulin Drug Market Is Estimated To Witness High Growth Owing To Increasing Prevalence of Diabetes

Anjali CMI 2023-09-01

The global Human Insulin Drug Market is estimated to be valued at US$ 42,283. PEST Analysis Political: The political environment plays a significant role in shaping the Human Insulin Drug Market. Key Takeaways The global Human Insulin Drug Market Share is expected to witness high growth, exhibiting a CAGR of 8. In conclusion, the Human Insulin Drug Market is projected to experience significant growth over the forecast period. The increasing prevalence of diabetes, along with advancements in insulin delivery devices and drug formulations, is driving market growth.

Pooja Khodke 2023-11-30

The global Human Insulin Drug Market is estimated to be valued at Us$ 49411. Segment Analysis The global human insulin drug market is segmented on the basis of product type, indication, distribution channel, and region. Further, based on indication, the market is divided into type 1 diabetes, type 2 diabetes, gestational diabetes, and others. Regional analysis: North America dominates the global human insulin drug market due to the rising prevalence of diabetes in the region. The global human insulin drug market size is expected to reach US$ 49411.

The Global Human Insulin Drug Market Growth Accelerated By Rapid Increase In Diabetes Cases

Dhanesha Patil 2024-02-08

The popularity and need for human insulin drugs is increasing substantially owing to the rising prevalence of diabetes worldwide. The global Human Insulin Drug Market is estimated to be valued at US$ 56921. Further, several new innovative insulin drugs and delivery systems have also been developed in recent years to improve patient's compliance and convenience. Segment Analysis The Global Human Insulin Drug Market Analysis is segmented into rapid-acting insulin, long-acting insulin, and premixed insulin. The global Human Insulin Drug Market is estimated to be valued at US$ 56921. Improving access to healthcare services and increasing disposable income levels are facilitating market growth in the region.

The Global Human Insulin Drug Market Growth Accelerated By Rising Prevalence Of Diabetes

Leena Shedmake 2024-01-10

Different types of insulin drugs are available including short-acting insulin, intermediate-acting insulin, long-acting insulin and premixed insulin. The global Human Insulin Drug Market is estimated to be valued at US$ 49411. Segment AnalysisThe global human insulin drug market is dominated by long acting human insulin segment. Long acting human insulin remains the preferred type of insulin used for diabetes treatment as it provides long-term blood glucose control. The global Human Insulin Drug Market is estimated to be valued at US$ 49411. Regional analysis: North America currently accounts for the largest share in the global market due to high healthcare expenditure and presence of key players.

Human Insulin Market Trends, Forecast and Competitive Analysis By 2027

fairfieldmarketresearch 2022-04-27

Get a Sample Copy of Human Insulin Market: https://www. The consistent rise in demand and requirement of human insulin and the powerful support from WHO are set to expand the human insulin market throughout the prophesied period. On the whole, the aforementioned factors are boosting the sales of human insulin, substantially contributing to the overall revenue of the human insulin market across the world. North America Consolidates Stronghold Position in the Human Insulin Market North America is predicted to dominate with a significant share in the human insulin market across the globe. Additionally, the propitious healthcare infrastructure and spikes in the per capita GDP of the human insulin market are anticipated to play an instrumental role in market sophistication.

human insulin market 2022 Analysis of Key Trends, Industry Dynamics and Future Growth 2030 with Top Countries Data

john clinton 2022-12-12

The report estimates the global human insulin market the human insulin market to attain a 11. com/sample_request/951Human Insulin Market Human Insulin MarketThe global human insulin market is segmented on the basis of type and region. By type, the global human insulin market is segmented into modern human insulin and traditional human insulin. The modern human insulin segment is further sub-segmented into long-acting human insulin, rapid-acting human insulin, and premixed human insulin, whereas the traditional human insulin segment is further categorized into short-acting and intermediate-acting human insulin. com

WHO TO FOLLOW

MORE FROM AUTHOR

The Global Athlete's Foot Market Is Poised For Steady Growth Driven By Increasing Health Awareness

Poonam 9h

Unveiling the Potential of Global Antisense & RNAi Therapeutics: A Promising Frontier

Poonam 9h

Harnessing The Power Of Plastic-Eating Bacteria

Poonam 10h

Sodium Hydroxide: A Versatile Chemical Compound

Poonam 12h

Zupyak is the world’s largest content marketing community, with over 400 000 members and 3 million articles. Explore and get your content discovered.

Press enter to search

Human Insulin Market Size, Key Players Analysis And Forecast To 2027 | Value Market Research

Trivendra Hussain 2021-11-03

The global Human Insulin Market research report, published by Value Market Research, is designed to offer various market framework such as market size, portion, trends, growth path, value and factors that impact the current market dynamics over the forecast period 2021-2027.

Most importantly, this report also provides the latest significant strategies adopted by major players along with their market share.The research report also covers the comprehensive profiles of the key players in the market and an in-depth view of the competitive landscape worldwide.

The major players in the human insulin market include Tonghua Dongboa, GlaxoSmithCline, Biocon, ADOCIA, Sanofi Aventis, Julphar, Novo Nordisk, SemBioSys, Oramed and Bristol-Myers Squibb Company.

This section includes a holistic view of the competitive landscape that includes various strategic developments such as key mergers & acquisitions, future capacities, partnerships, financial overviews, collaborations, new product developments, new product launches, and other developments.Get more information on "Global Human Insulin Market Research Report" by requesting FREE Sample Copy at https://www.valuemarketresearch.com/contact/human-insulin-market/download-sampleMarket DynamicsThe growing number of patients of diabetes across the globe along with the increasing obese population, mainly due to the transformation in lifestyle, is the main drivers of the human insulin market.

Besides, the arrival of pen devices coupled with the safety pen needles for better release of insulin is the fuelling factor for the global human insulin market.

This is owing to numerous benefits while delivering insulin through safety pens against other standard needles.

Human Insulin Market Industry Booming Demand by Top Regions and Major Segments Till 2021

Sumit Choudhari 2019-04-11

Human insulin is also known as synthetic insulin which is prepared in laboratory and has same characteristics like natural insulin.

Human insulin was developed through the 1960s and 1970s and approved for pharmaceutical use in 1982.

Before the invention of human insulin animal insulin, usually a purified form of porcine was used.Market Research Future (MRFR) postulates that the global human insulin market is slated to register 12.5% CAGR during the forecast period (2017-2023).

Human insulin is referred to as synthetic insulin which is generally manufactured in the laboratories by developing insulin protein with E. coli bacteria.

Among these, type 2 diabetes is predicted to occupy the largest market share owing to its increasing prevalence across the globe.By mode of end-users, the global human insulin market has been segmented into forensic laboratories, hospitals, research centers, and others.Get Sample Copy @ https://www.marketresearchfuture.com/sample_request/951Human Insulin Market Key PlayersThe prominent players operating in the human insulin market are ADOCIA, Novo Nordisk A/S, Merck & Co, Sanofi, Bristol-Myers Squibb Company, GlaxoSmithKline, Biocon Ltd, Pfizer Inc, Oramed Pharmaceuticals Inc, Tonghua Dongbao Pharmaceuticals Co. Ltd., and Julphar.Human Insulin Market Regional AnalysisNorth America and EU regions are dominating the market over a period of time while, Asia is the fastest growing region for Human insulin Market in coming yearsIncreasing prevalence of diabetes and increasing R investment for more effective insulin are driving the growth of the human insulin market in North America.

Diabetes has become one of the major public health problems in North America, due to increasing number of geriatric population and rising prevalence of obesity.Diabetes is the major public health threat for the world.

Human Insulin Market - Share Assessments for the Regional and Country Level Segments

Jams Smith 2018-04-06

The global human insulin market is being driven by increasing prevalence of diabetic population, and rise in aging population.

Diabetes is a chronic and non-communicable disease, and its global prevalence is increasing enormously.

Rising prevalence of obesity, rising awareness about diabetic care, and technological advancement in insulin delivery devices are some of the factors driving the growth of the global human insulin market.Download Sample of This Research Report: https://www.psmarketresearch.com/market-analysis/human-insulin-market/report-sampleIncreasing prevalence of diabetes, increasing number of geriatric population, rising prevalence of obesity and increasing R investment for more effective insulin are driving the growth of the human insulin market in North America.

The North American human insulin market is expected to grow by a CAGR of 11.8% during the period 2015 to 2020.

In Europe, according to International Diabetic Federation in 2013, approximately 52 million people were suffering from diabetes in Europe.

The European human insulin market is expected to grow by a CAGR of 12.6% during the period 2015 to 2020.

The Human Recombinant Insulin Market is driven by increasing prevalence of diabetes

naufan003 2024-02-16

The human recombinant insulin market comprises insulin products that are produced through recombinant DNA technology. The production of recombinant human insulin involves insertion of the human insulin gene into either yeast cells or E. The global recombinant human insulin market is estimated to be valued at US$ 47926. Impact of geopolitical situation on Human Recombinant Insulin Market growth The current geopolitical instability across many parts of the world is impacting the growth of the human recombinant insulin market. Fastest growing region for Human Recombinant Insulin market The Asia Pacific region excluding Japan is projected to be the fastest growing market for human recombinant insulin during the forecast period due to several factors.

Human Recombinant Insulin Market Is Estimated To Driven By Rising Prevalence Of Diabetes

ashwinicmi 2023-12-18

The global human recombinant insulin market is primarily driven by the rising prevalence of diabetes across the world. The global human recombinant insulin market is estimated to be valued at US$ 41,602. This is expected to intensify competition in the overall insulin market in the coming years. Another important trend gaining traction is the increasing research into novel insulin delivery devices such as inhalable insulin and oral insulin pills. Porter's Analysis Threat of new entrants: The threat of new entrants to the human recombinant insulin market is moderate. The global human recombinant insulin market is estimated to be valued at US$ 41,602.

human insulin market – Revenue, Opportunity, Segment and Key Trends

Ruchita Roy 2020-12-07

Market Research Future (MRFR) has announced a new release on the global human insulin market.

The report talks about the future growth prospects of the global human insulin market on the basis of the historical statistics of the market and the market’s key growth drivers and restraints.

The report estimates the global human insulin market to reach a valuation of USD 40 billion by 2021, rising at a CAGR of around 10-12% over the 2016-2021 forecast period.Request Free Sample Copy at:https://www.marketresearchfuture.com/sample_request/849The growing prevalence of diabetes is likely to be the major driver for the global human insulin market over the forecast period.

The threat of diabetes has grown in developed countries because of the increasing consumption of sugar-rich, unhealthy foods, allied to a mostly sedentary lifestyle.

The increasing Westernization of the dietary patterns in developing countries has also led to a significant growth in the prevalence of diabetes in emerging regions such as Asia Pacific, which is likely to drive the human insulin market over the forecast period.Segmentation:The global human insulin market is segmented on the basis of type and region.

Modern human insulin is likely to dominate the global human insulin market over the forecast period due to its higher efficacy and less risk of side effects.

Human Insulin Market Outlook, Analysis, Top Key Players, Growth and Trend by 2022-2030| MRFR

Cordelia slayer 2023-03-02

The human insulin market size could touch USD 156478. Development of biosimilars is a significant trend which is expected to increase the competition in the market and in turn, boost the market growth. SegmentationThe global human insulin market outlook has been segmented based on type, methods, indication, and end users. By methods, the market has been segmented into traditional human insulin and modern human insulin. Competitive LandscapeThe notable players operating in the global human insulin market include Biocon Ltd, ADOCIA, Julphar, Bristol-Myers Squibb Company, Oramed Pharmaceuticals, Inc, Sanofi, Tonghua Dongbao Pharmaceuticals Co.

From Genetics to Treatment: Exploring the Power of Human Recombinant Insulin

Steve martin 2023-06-22

The journey from genetics to treatment has led to the discovery and utilization of human recombinant insulin, showcasing its immense power in revolutionizing diabetes treatment. These modified cells act as factories, producing insulin that is virtually indistinguishable from the insulin naturally produced by the human body. With human recombinant insulin, the future of diabetes care is characterized by tailored treatment regimens that address the unique needs of each patient. The power of human recombinant insulin lies in its ability to restore balance to blood glucose levels. Through ongoing research and technological advancements, the potential applications of Human Recombinant Insulin continue to expand, providing hope for improved treatment strategies and better outcomes for those living with diabetes.

Human Insulin Market: Trends and Opportunities

[email protected] snehal@119 2021-05-27

The report “Human Insulin Market - Drugs (Biologics, Biosimilars), Type (Short Acting, Long Acting, Premixed), Brands (Lantus, NovoRapid, Humalog), Delivery Devices (Pens, Pen Needles, Syringes), Applications (Type 1 Diabetes, Type 2 Diabetes) - Forecasts to 2020” analyzes and studies the major market drivers, restraints, opportunities, and challenges in North America, Europe, Asia-Pacific, and the Rest of the World (RoW).Ask for PDF Brochure: -https://www.marketsandmarkets.com/pdfdownloadNew.asp?id=229295783 The Global Human Insulin Market Is Poised to reach ~USD 39.13 Billion by 2020, growing at a CAGR of 8.1% from 2015 to 2020 and studies the global human insulin market over the forecast period of 2015 to 2020.On the basis of products, the global human insulin market is classified into two segments, namely, drugs and delivery devices.

Human insulin drugs market has been further divided on the basis of drug type (rapid-acting, intermediate-acting, long-acting, short-acting, and premixed) and drug brands (Lantus, NovoRapid/Novolog, Humalog, Humulin, Insuman, Actrapid, Insulatard, Mixtard, and Other Biosimilar Brands).

Furthermore, human insulin delivery devices market is segmented into insulin pens (reusable & disposable), pen needles (standard & safety), and conventional syringes.

Additionally, global human insulin market is classified on the basis of applications into type I diabetes applications and type II diabetes applications.Factors such as growing diabetes patient population, increasing population exposure to key risk factors leading to diabetes, rising market demand for human insulin analogs, technological advancements in the field of human insulin delivery devices, and favorable medical reimbursements are driving the growth of human insulin market during the forecast period.

However, stringent regulatory requirements for product approval are restraining the growth of this market.In 2015, North America is expected to hold the largest share of the human insulin market, followed by Europe.

Additionally, Asia-Pacific is expected to grow at the highest CAGR during the forecast period (2015 to 2020).

Human Insulin Market Share - Growth Opportunities by Manufacturers, Regions, Type, Application and Trends Forecast

Market Research Future 2022-02-24

5% over the forecast period of 2017-2023, proclaims Market Research Future (MRFR) in a meticulously analyzed research report. com/sample_request/951 SegmentationThe global human insulin market has been segmented based on type, methods, indication, and end users. By methods, the market has been segmented into traditional human insulin and modern human insulin. Regional AnalysisThe global human insulin market spans across the regions of the Americas, Europe, Asia Pacific, and the Middle East & Africa. About US:Market Research Future (MRFR) enable customers to unravel the complexity of various industries through Cooked Research Report (CRR), Half-Cooked Research Reports (HCRR), Raw Research Reports (3R), Continuous-Feed Research (CFR), and Market Research & Consulting Services.

Global Human Insulin Market Outlook 2021

danyon shel 2021-02-18

Global Human Insulin Market research report includes specific segments by region (country), by company, by Type and by Application.

This study provides information about the sales and revenue during the historic and forecasted period of 2015 to 2026.

Understanding the segments helps in identifying the importance of different factors that aid the market growth.

Download FREE Sample of this Report @ https://www.grandresearchstore.com/report-sample/global-human-insulin-2021-762Segment by Type, the Human Insulin market is segmented into:Insulin Analogs and BiosimilarsHuman Insulin BiologicsSegment by Application:Short actingIntermediate actingLong actingPre-mix InsulinGlobal Human Insulin Market: Regional AnalysisThe Human Insulin market is analysed and market size information is provided by regions (countries).

The report includes country-wise and region-wise market size for the period 2015-2026.

It also includes market size and forecast by Type and by Application segment in terms of sales and revenue for the period 2015-2026.The key regions covered in the Human Insulin market report are:North AmericaU.S.CanadaEuropeGermanyFranceU.K.ItalyRussiaAsia-PacificChinaJapanSouth KoreaIndiaAustraliaTaiwanIndonesiaThailandMalaysiaPhilippinesVietnamLatin AmericaMexicoBrazilArgentinaMiddle East & AfricaTurkeySaudi ArabiaU.A.EGlobal Human Insulin Market: Competitive AnalysisThis section of the report identifies various key manufacturers of the market.

Human Insulin Market Share Analysis of The Top Industry Players, Growth Opportunities and Country Level Segments

Pramod Kumar 2018-07-25

The global human insulin market was valued at $23,981.6 million in 2014.

The market is expected to grow at a CAGR of 12.5% during the period 2015 to 2020, to reach $48,487.7 million value by 2020.

On the basis of type of human insulin, the modern human insulin commands the larger share in the global market.

The modern human insulin can be further categorized as long acting human insulin, rapid acting human insulin and premixed human insulin; wherein, the long acting human insulin commands the largest share in modern human insulin market but the premixed human insulin exhibited the highest growth rate.

It is absorbed slowly and works for long time to control the sugar level between meal and sleep.

It is administered once or twice a day and the onset time for long acting human insulin is 1 hour, and has its effect for 20 hours to 26 hours.Download Sample of This Research Report: https://www.psmarketresearch.com/market-analysis/human-insulin-market/report-sampleIncreasing prevalence of diabetes, increasing number of geriatric population, rising prevalence of obesity and increasing R investment for more effective insulin are driving the growth of the human insulin market in North America.

Human Insulin Market Development, Outline, Competitive perspective, and Forecast, 2020 to 2027

shriya laturkar 2021-06-16

Human Insulin Market: Information by Type (Traditional Human Insulin (Premixed Traditional, Intermediate Acting and Short-Acting), Modern Human Insulin (Premixed Modern, Long-Acting and Rapid Acting) and Brand (Lantus, Novorapid, Humalog, Novomix, Levemir, Apidar, Humulin and Insuman)) and Region (Americas, Europe, Asia-Pacific and Middle East & Africa) - Global Forecast till 2027Demand for human insulin also referred to as synthetic insulin is on the rise.

Human insulin in the foremost requirement for a diabetic person.

After its commercial launch, the product quickly replaced the existing drug, which was purified form of porcine.

However, stringent regulation, drug approval delays, and high cost of insulin analog are some of bottlenecks for the market.

In the forthcoming years demand for human insulin is expected to grow further in countries such the U.S., Canada, and Mexico.

Rising number of elderly population and sedentary lifestyle is also linked with the increase diabetes prevalence.

Human Insulin Market Size To Expand Momentously Over 2021-2030

Hemantkolhe 2021-10-13

It provides a product overview and highlights of product and application segments of the market including price, revenue, sales, sales growth rate, and market share by product.

The market statistics within the report are displayed in a statistical format to offer a better understanding of the market dynamics.

"For Right Perspective and Competitive Insights, Get Sample Report at: https://www.alliedmarketresearch.com/request-sample/417 Human Insulin Market Research has offered an exhaustive analysis of Manufacturers, Suppliers, Regions, Type, and Application, Forecast to 2030.

And also provides essential study on the current status of the market, cover market size with respect to valuation as sales volume, and providing a precise prediction of the market scenario over the forecast period from 2021 to 2030.The report provides revenue forecasts with sales, sales growth rate, and revenue growth rate forecasts of the global Human Insulin Market.

The forecasts are provided to understand the future outlook and prospects for the market.Covid-19 Scenario:1) The Covid-19 pandemic and followed by lockdown has affected several manufacturing industries.2) The prolonged lockdown resulted in a disrupted supply chain and increased the prices of raw materials.3) However, as the world has been recovering from the pandemic, the market is estimated to get back on track.Detailed COVID-19 Impact Analysis on Market at: https://www.alliedmarketresearch.com/request-for-customization/417?reqfor=covid Major Key Players: -Various strategies adopted by these companies to gain stronghold of the market include partnerships, collaborations, approvals, mergers & acquisitions, joint ventures, expansions, and othersThe leading companies in Global Human Insulin Market are analyzed in the report along with their business overview, operations, financial analysis, SWOT profile and STD Reimbursement Scenario Analysis, And Top Study Testing Technologies products and services.The key players of the market include Aetna Inc., lighTouch Medical Inc., Cnsystems Medizintechnik AG, Memscap SA, Fresenius Medical Care, SunTech Medical, W. A. Baum Co. Inc., Siemens Corporate Research Inc., Omron Healthcare Inc., Corporation, are some of the key leaders in the global IDH market.The report lays emphasis on the key trends and opportunities that may emerge in the near future and positively impact the overall industry growth.

Additionally, challenges and restraining factors that are likely to curb the growth in the years to come are put forth by the analysts to prepare the manufacturers for future challenges in advance.Interested to Procure the Data?